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Abstract
Developments in mutation analysis have added to the complexity of treatment selection. In this mixed methods
study, with a sample of 358 oncologists from 7 countries, we aimed to identify international clinical practice
challenges regarding colorectal cancer treatment. Findings indicate that treatment selection is hindered by 6
substantive challenges, which have the potential to inform the development of interventions to improve
practice.
Background: Over the past decade, individualization of treatment for colorectal cancer (CRC) has been improved by:
(1) approval of several new agents by national agencies such as the US Food and Drug Administration (FDA); and (2)
rapid advances in mutation analysis. However, data are sparse on the clinical challenges experienced by oncologists
as they address the increased complexity created by the growing potential for individualization of CRC treatment.
Materials and Methods: To identify clinical challenges experienced by oncologists regarding CRC treatment, an
international assessment was conducted. A mixed methods approach was used, with the collection and analysis of
qualitative (semistructured telephone interviews) and quantitative (online survey) data. Participants were oncologists
actively practicing in 1 of 7 targeted countries with a minimum caseload of 10 CRC patients per year. Results: The
sample included 358 oncologists from China (n ¼ 68), France (n ¼ 44), Germany (n ¼ 44), Italy (n ¼ 45), Spain (n ¼ 44),
the United Kingdom (n ¼ 45), and the United States (n ¼ 68). Mixed methods ﬁndings indicated that oncologists’
treatment selection is hindered by practice challenges in: (1) mutation analysis and subsequent adaptation of treat-
ment; (2) optimal sequential use of treatment choices; (3) treatment individualization based on patient and tumor
proﬁle; (4) management of side effects and toxicities; (5) chemoresistance, cross-resistance, and combinations to
overcome resistance; and (6) access to new emerging treatments. Conclusion: In the context of increased complexity
created by the approval of new agents and advances in mutation analysis, challenges are experienced by practicing
oncologists in the individualization of treatment for CRC patients. Details of these challenges should stimulate dia-
logue among oncologists, and development of interventions to improve clinical practice.
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Clinical Colorectal Cancer March 2016tumor markers have reﬁned oncologists’ understanding of tumor
proﬁles.1 Analysis of Kirsten rat sarcoma viral oncogene homolog
(KRAS) mutation status is more frequent,2 but should not be the
only mutation analysis made because other markers also have
importance.3-9 Identiﬁcation of shared molecular changes in CRC
tumors have led to a new molecular classiﬁcation of CRCs being
proposed.10 As a result of new developments in mutation analysis,
treatments initially thought to be minimally effective are now
considered valid choices for speciﬁc subpopulations, and other
treatments initially thought to be effective for all patients are now
excluded for speciﬁc subpopulations.11,12 In Europe, label updates
are expected to be issued in 2014 that would restrict usage of certain1533-0028/ª 2016 The Authors. Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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agents to speciﬁc tumor mutation proﬁles. Multiplex assay kits that
allow simultaneous identiﬁcation of multiple mutations provide
oncologists with a large amount of information about the molecular
speciﬁcities of a patient’s tumor.13
Second, a number of new therapeutic agents have been approved by
national drug-reviewing agencies such as the US Food and Drug
Administration, increasing oncologists’ treatment options.14,15 These
new agents include mutation and/or marker-speciﬁc drugs that
might lack a positive risk beneﬁt ratio in patients not meeting that
speciﬁc tumor proﬁle.16 Therefore, it is essential that oncologists
fully understand the unique implications of each treatment option.
However, with increased potential for individualization of treat-
ment plan comes increased complexity in treatment selection,
because oncologists now have new data to consider in their clinical
reasoning (ie, mutation analysis results), and more choices of agents,
each with their own risks and beneﬁts.1
Together with this added complexity, gaps in knowledge and
skills, attitudinal and behavioral factors, access, and other system
factors can be barriers to optimally individualized treatment plans.
Decisions made at a health system level regarding the promotion of
certain mutation tests directly affect clinical decisions. Tests for
certain mutations might be standard in some countries, but not in
others. Consequently, patients whose tumor bears a particular
mutation unbeknownst to their treating oncologists because testing
for that particular mutation is not standard practice in his country,
might receive a treatment for which clear evidence exists for a lack of
response in that patient subpopulation. This creates difﬁculties for
oncologists because treating a patient with an agent not optimally
indicated for their mutation proﬁle could be futile, or in some cases,
cause harm.
Internationally, there is a current lack of data on oncologists’
knowledge, skills, attitudes, and clinical behaviors in conﬁdently
incorporating the increasing complexities of treatment selection and
individualization (based on patient and tumor proﬁles) into their
clinical reasoning. To ﬁll this lack of data, and inform future
educational and performance improvement initiatives, an interna-
tional assessment of current challenges was conducted.
The overall objective of this applied research study was to
determine the clinical practice gaps in the knowledge, skills, and
attitudes of oncologists involved in CRC treatment and manage-
ment, in 7 countries (China, France, Germany, Italy, Spain, the
United Kingdom, and the United States). In this report we present
the challenges we identiﬁed as hindrances to oncologists’ capacity to
individualize treatment according to patient and tumor character-
istics, in light of the recent advances in mutation analysis and
approval of new agents by national agencies.
Materials and Methods
The method in this applied research study was a combination of
the collection and analysis of qualitative and quantitative data in a
mixed methods framework, through which the strengths of each
technique (ie, depth of qualitative exploration and analytic power of
quantitative validation) are drawn.17,18 To increase the validity and
trustworthiness of ﬁndings, triangulation19,20 of approaches (qual-
itative, quantitative) and of data collection methods (interviews,
surveys) was used. International ethical approval was obtained from
an independent organization (IRB Services, Boca Raton, FL), toensure protection and conﬁdentiality of participants, in accordance
with international guidelines and policies.21
Recruitment and Inclusion Criteria
Participants for both study components (qualitative, quantitative)
were recruited via an international online panel provider in
compliance with the European Society for Opinion and Market
Research code of conduct22 and ethical standards for social research.
All panel members were veriﬁed for their credentials. Invitations
included a Web link where interested participants could learn about
the study, electronically provide informed consent, and answer
eligibility questions. Participants who consented to participate and
met eligibility requirements were redirected to either an interview
availability form or the online survey.
To be eligible, participants were required to be actively practicing in
1 of the 7 targeted countries (United Kingdom, France, Germany,
Italy, Spain, China, and the United States), and have a minimum
caseload of 10 CRC patients per year. Appropriate sample represen-
tation was conﬁrmed through the process of purposive sampling, in
which selected criteria (for this study: years of clinical practice, type of
practice setting, and CRC caseload) were monitored regularly
during the recruitment period to ensure that their respective distribu-
tions did not deviate signiﬁcantly from the population distribution.17,23
Qualitative Component
After a review of the literature we generated hypotheses regarding
gaps in knowledge, skills, and clinical conﬁdence of oncologists
involved in the treatment and management of patients with CRC.
The hypotheses informed the design of a 45-minute, semistructured
interview guide. Interview topics were focused on the clinical
challenges experienced by providers that might hinder their capacity
to optimally treat and manage patients with CRC. Interviews were
conducted in the ofﬁcial language of the participant’s country, by a
trained interviewer.
Interviews were audio recorded for transcription and analysis. To
inform the selection of a subset of interviews for transcription, in-
terviewers rated the quality of each discussion in relation to the
study objectives immediately after completion of the interview.
Transcripts of interviews conducted in languages other than English
or French were translated to English. Interviewer’s debrieﬁng ses-
sions were conducted with all interviewers to generate in-depth
discussion around the emerging themes.
N-Vivo 7.0 software (QSR International, Cambridge, MA) was
used to code and analyze the transcripts, using an approach that
drew from the principles of thematic analysis24 and directed content
analysis.25 The approach included 4 steps: (1) identiﬁcation of
predetermined codes based on reviewed literature and interviewer’s
debrieﬁng sessions; (2) coding of data using codes from step 1; (3)
analysis of data that could not be coded and revision of coding tree;
and (4) identiﬁcation of emerging themes with substantial data.
Quantitative Component
Findings from the qualitative phase and information gathered
from the literature were used to inform the design of a 15- to 20-
minute survey deployed in a subsequent conﬁrmatory quantitative
phase. The survey was designed through the collaborative expertise
of clinical content faculty (including coauthor J.L.M.) andClinical Colorectal Cancer March 2016 - 55
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consisted of questions that used multiple nominal choice and
Likert-type response formats, and addressed self-reported: (1) rele-
vance of skills in clinical practice (not relevant, somewhat relevant,
essential); (2) current level of knowledge (not acceptable, could be
improved, acceptable), skill (needs signiﬁcant improvement, needs
minor improvement, optimal), and conﬁdence (1 ¼ low; 5 ¼ high);
and (3) challenges in clinical reasoning (1 ¼ no challenge; 5 ¼
signiﬁcant challenge). Surveys were completed online in the ofﬁcial
language of the participants’ region.
Quantitative data were analyzed using frequencies, cross-
tabulations, c2, and analysis of variance (ANOVA), using SPSS 12.0
software (SPSS, Chicago, IL). Furthermore, a quadrant analysis, based
on principles from gap analysis theory18,26 was used, for a comparison
of the respondents’ perceived relevance of speciﬁc skills and their self-
reported need for improvement in said skill. Through this analysis, the
presence of a gap was identiﬁed when a particular item for a particular
respondent was considered relevant and needing improvement. Sub-
group differences (according to years of practice, practice types, or
caseload) were calculated using ANOVA for ordinal variables, and
Pearson c2 test (hereafter referred to as c2) for nominal variables.
Mixed Methods Analysis
Gaps within the qualitative analysis, and gaps identiﬁed through
the quantitative approach were synthesized and grouped through
multidisciplinary interpretation to generate trustworthy and reliableTable 1 Sample Distribution and Characteristics of Medical Oncolo
Characteristic Phase 1: Qualitative (n [ 36)
Sex
Male 31 (86%)
Female 5 (14%)
Country
China 8 (22%)
Germany 4 (11%)
Spain 4 (11%)
France 4 (11%)
United Kingdom 4 (11%)
Italy 4 (11%)
United States 8 (22%)
Practice Setting
Private 6 (17%)
Community-based 7 (19%)
Cancer Center 3 (8%)
Academic 20 (56%)
Years of Practice
5-10 Years 13 (31%)
11-20 Years 16 (44%)
More than 20 years 7 (19%)
Caseload
10-25 Patients per month 12 (33%)
26-50 Patients per month 12 (33%)
>50 patients per month 12 (33%)
Data are presented as n (% of column group).
Clinical Colorectal Cancer March 2016ﬁndings on the challenges of oncologists in the treatment and
management of people with CRC.
Results
Sample Size and Demographic Characteristics
The sample included 358 medical oncologists (Table 1). Response
rates (number of physicians who followed theWeb link from the study
invitation, divided by the number of study invitations sent) varied
from 4% in the United States to 58% in Italy. Variability of response
rates was explained by the differences in panel sizes (and thus in the
number of invitations sent), and recruitment being stopped when
targeted samples were reached in each country. Most participants were
male (n:262; 73%), almost half of the sample had between 11 and 20
years of practice experience (n:175; 49%), and were from academic
practice settings (n:169; 47%). Furthermore, most of the participants
(n:246; 69%) reported that CRC patients comprised 20% or more of
their annual caseload. The distribution of some demographic variables
was different between countries because of the different systems in
place. For example, 59% of US participants (n:40) reported practicing
in a private setting, compared with none (n:0; 0%) of the participants
from China, France, the United Kingdom, and Italy.
Identiﬁed Gaps, Challenges, and Barriers
The analysis resulted in the identiﬁcation of 6 key challenges
indicative of the main competencies needed for oncologists to indi-
vidualize treatment according to patient and tumor characteristics.gists for Each Phase
Phase 2: Quantitative (n [ 322) Total (n [ 358)
231 (72%) 262 (73%)
91 (28%) 96 (27%)
60 (19%) 68 (19%)
40 (12%) 44 (12%)
40 (12%) 44 (12%)
40 (12%) 44 (12%)
41 (13%) 45 (13%)
41 (13%) 45 (13%)
60 (19%) 68 (19%)
62 (19%) 68 (19%)
65 (20%) 72 (20%)
46 (14%) 49 (14%)
149 (46%) 169 (47%)
103 (32%) 116 (32%)
159 (49%) 175 (49%)
60 (19%) 67 (19%)
97 (30%) 109 (30%)
134 (42%) 146 (41%)
91 (28%) 103 (29%)
Patrice Lazure et alAlthough the key ﬁndings were obtained using an integrated mixed
method interpretation process, the results presented in this section
are focused on the quantitative ﬁndings. Quotes from the qualitative
phase of the study illustrating each challenge are presented in Table 2.
Analyses of Mutations and of Subsequent Adaptations of
Treatment
Among a list of topics presented, mutation analysis and oncotype
testing was the most frequently selected (n:202; 63%) as being
challenging to remain abreastwith current evidence (Table 3).ThiswasTable 2 Quotes From the Qualitative Phase of the Study Illustrating
Type
Gap, Challenge,
or Barrier
K/S/C Analyses of mutations and
subsequent adaptations
to treatment
“The third challenge is individual pat
use of speciﬁc drugs. In other wor
can I deﬁne new genetic changes
“.with this issue of EGFR mononu
only the wild-KRAS, there should
complicated.(.) We have to adm
make sure that we’re on the right pa
for their beneﬁt and
K/S Optimal sequencing of
treatment choices
“And this is the question that does c
there is a need there for education fo
providing the information on wha
“As you can imagine, a certain seq
us decide w
K/S Individualizing treatment based
on patient and tumor proﬁle
So when we decide therapy, it’s
comorbid illnesses, whether th
multiple organs like liver and lu
“Comorbidities is a big issue. How
to undergo? (.) If they have c
special attention to ﬂuid manage
things that
K/C Knowledge of, and access to
new emerging treatments
“The management of colorectal ca
very recently. Our practice has no
I understa
“The third challenge is the cost,
most patients. The high cost is rela
“.particularly in patients who have
agents (.) have a fairly well est
that could possibly be used, b
S Management of side effects
and toxicities
“The assessment of neurotoxicity is
sort of lag period whereby the d
manifested perhaps a couple of m
“Yes, if you take each molecule, al
for another, it’s hematologic toxicity
say that any drug in chemo
K Chemoresistance,
cross-resistance, and
combinations for overcoming
resistance
“One is patients’ developing drug re
There are such patients. And anoth
care were be
Abbreviations: A ¼ attitude; B ¼ behavior; C ¼ context; K ¼ knowledge; S ¼ skill.the case in all 7 countries, although in Italy and the United Kingdom,
the proportion was the same for optimal sequencing and com-
bination of treatment. Almost three-quarters of oncologists (n:231;
72%) reported their knowledge of oncotype testing and prognostic
models of the risks of cancer recurrence in CRC as being unacceptable
or needing improvement (Table 4, item 1). This proportion was
> 50% in all countries surveyed, with the highest proportion
needing improvement (n:38; 93%) being in the United Kingdom.
More than half of the participants (n:189; 59%) reported that
adapting treatment recommendations to mutation analysis resultsEach Challenge Presented in This Report
Illustrative Quote
ient factors, for example, genetics and mutations of the genome that inﬂuence the
ds, do I do without a speciﬁc drug because I’m dealing with a genetic change or
that would give me a better result if I treat with this drug rather than another?”
—Medical Oncologist, Germany
clear antibodies (.) everything got more and more complicated, so it was not
also be a mutation in BRAF, so the use of a new drug gets more and more
inister drugs with a molecular marker, like the case of the KRAS mutation, to
th, but it’s a bit blind.(.) we’re telling patients we’re administering something
we’re not really sure if they are going to beneﬁt from it or not.”
—Medical Oncologist, Spain
ome up, in terms of sequencing therapy and what’s appropriate or not and again,
r discussing that. (.) I’m not suggesting that there is a right answer, but at least
t the rationale may be for a certain sequence and how you would approach it.”
—Medical Oncologist, United States
uence can be more beneﬁcial but we do not have much clinical data to help
hich is the correct sequence for a particular patient.”
—Medical Oncologist, Germany
not just the diagnosis of colorectal cancer, it involves how old the patient is,
e patient has neuropathy or not, site of disease, type of metastasis, is it
ngs, and also the genetic markers like EGFR and KRAS, so each person is
treated, gets a personalized plan.”
—Medical Oncologist, United States
aggressively can I treat the patient? Which therapy can I expect the patient
omorbidities such as diabetes or cardiac insufﬁciency, then I have to pay
ment, (.) I have to make sure that the blood sugars are stable. These are
are very time-consuming but have to be kept in mind.”
—Medical Oncologist, Germany
ncer is a fast changing ﬁeld and many of the new medicines have come out
t integrated all of them into standard practice and there’s a lot of controversy
nd, also in terms of when to use which medicines. ”
—Medical Oncologist, US
especially the cost of targeted agents, is high. It’s beyond the affordability of
ted to the price set by the manufacturers as well as the insurance coverage.”
—Medical Oncologist, China
chemo-refractory disease where we now know that, for example, EGFR-targeting
ablished role (.) we have to say to patients that yes, there are other drugs
ut unfortunately in the government-funded health care service, we don’t
have access to them”
—Medical Oncologist, United Kingdom
quite difﬁcult and I’m sure it varies from between doctors. (.) There’s often a
amage is kind of accrued in a sort of clinical way and it then only becomes
onths down the line by when it’s too late to actually do anything about it.”
—Medical Oncologist, United Kingdom
l of them, in certain situations give problems. One, it is a neurological toxicity,
in some patients, for a third molecule, it will be a dermal toxicity. (.) I would
therapy, there is a very narrow window between efﬁcacy and toxicity.”
—Medical Oncologist, France
sistance after receiving the therapy. And the other is primary drug resistance.
er is uncontrollable side effects. (.) 90% of the patients who died under my
cause of the 3 challenges, so they are very important.”
—Medical Oncologist, China
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Table 3 Number and Percentage of Oncologists in Each Country Who Selected Each Knowledge Area as 1 of the 2 Most Difﬁcult to Keep Up To Date With Current Evidence
Knowledge Area
Participants Who Selected the Area (Participants Could Select up to 2 Areas), n (%)
CHN
(n [ 60)
FRA
(n [ 40)
GER
(n [ 40)
ITA
(n [ 41)
SP
(n [ 40)
UK
(n [ 41)
US
(n [ 60)
Total
(n [ 322)
Signiﬁcant
Differencea
1. Mutation Analysis and
Oncotype Testing
39 (65%) 23 (58%) 26 (65%) 18 (44%) 29 (73%) 28 (68%) 39 (65%) 202 (63%) NS
2. Optimal Sequencing and
Combination of Treatment
34 (57%) 17 (43%) 20 (50%) 18 (44%) 14 (35%) 28 (68%) 30 (50%) 161 (50%) NS
3. Diagnostic Tests for Precise
Staging in Colorectal Cancerb
24 (40%) 12 (30%) 12 (30%) 7 (17%) 2 (5%) 4 (10%) 11 (18%) 72 (22%) CHN > SP;
CHN > UK
4. Surgical Procedures for Rectal
Cancerb
2 (3%) 6 (15%) 5 (13%) 12 (29%) 10 (25%) 4 (10%) 10 (17%) 49 (15%) NSD
5. Chemotherapy Treatments for
Colon Cancer
10 (17%) 5 (13%) 7 (18%) 5 (12%) 3 (8%) 5 (12%) 11 (18%) 46 (14%) NS
6. Surgical Procedures for Colon
Cancerb
4 (7%) 2 (5%) 3 (8%) 12 (30%) 10 (25%) 5 (12%) 8 (13%) 44 (14%) NSD
7. Radiation Treatment for
Rectal Cancerb
1 (2%) 11 (28%) 4 (10%) 5 (12%) 11 (28%) 3 (7%) 6 (10%) 41 (13%) UK > CHN;
US > CHN
8. Chemotherapy for Rectal
Cancer
6 (10%) 4 (10%) 1 (3%) 4 (10%) 0 (0%) 4 (10%) 4 (7%) 23 (7%) NSD
Abbreviations: CHN ¼ China; FRA ¼ France; GER ¼ Germany; ITA ¼ Italy; SP ¼ Spain; UK ¼ United Kingdom.
aSigniﬁcant differences between pairs of countries using analysis of variance (ANOVA) and Tahmane T2 post hoc tests (P < .05). NS (not signiﬁcant) indicates measures for which the ANOVA was not signiﬁcant, and thus, for which the post hoc tests were not performed. NSD
(no speciﬁc difference) indicates measures for which the ANOVA was signiﬁcant, but speciﬁc post hoc differences could not be identiﬁed.
bSigniﬁcant differences between countries (c2; P < .05).
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Table 4 Number and Percentage of Oncologists in Each Country Reporting Their Knowledge Levels on Speciﬁc Items as Not Acceptable or Needing Improvement
Knowledge Area
Participants Reporting Not Acceptable/Could Be Improved, n (%)
CHN
(n [ 60), %
FRA
(n [ 40), %
GER
(n [ 40), %
ITA
(n [ 41), %
SP
(n [ 40), %
UK
(n [ 41), %
US
(n [ 60), %
Total
(n [ 322), %
Signiﬁcant
Differencea
Mutation Analysis (Use and Access) and Subsequent Adaptation of Treatment Selection
1. Oncotype testing and prognostic
models of the risks of cancer
recurrence in CRCb
35 (58%) 35 (88%) 31 (78%) 31 (76%) 30 (75%) 38 (93%) 31 (52%) 231 (72%) FRA > CHN;
UK > CHN
Optimal Sequencing of the Different Treatment Options
2. Sequencing of therapy after
surgeryb
15 (25%) 15 (38%) 7 (18%) 8 (20%) 8 (20%) 18 (44%) 12 (20%) 83 (26%) NSD
Individualizing Treatment Based on Patient and Tumor Proﬁle
3. Best practices for the treatment
of patients who have severe
comorbid conditionsb
34 (57%) 25 (63%) 15 (38%) 13 (32%) 17 (43%) 16 (39%) 22 (37%) 142 (44%) NSD
4. Best treatment combination for
each individual patient
28 (47%) 20 (50%) 13 (33%) 16 (39%) 9 (23%) 15 (37%) 19 (32%) 120 (37%) NS
5. The proﬁle of patients who will
respond best to each available
therapeutic option
18 (30%) 20 (50%) 19 (48%) 13 (32%) 16 (40%) 20 (49%) 25 (42%) 131 (41%) NS
6. Best practices for the treatment
of patients older than the age of
70 years
16 (27%) 17 (43%) 11 (28%) 8 (20%) 9 (23%) 14 (34%) 12 (20%) 87 (27%) NS
Management of Side Effects and Toxicities
7. Side effects associated with each
colorectal cancer treatment optionb
22 (37%) 8 (20%) 15 (38%) 13 (32%) 6 (15%) 3 (7%) 9 (15%) 76 (24%) CHN > UK;
GER > UK
8. Toxicity associated with available
combination therapyb
14 (23%) 13 (33%) 14 (35%) 14 (34%) 5 (13%) 5 (12%) 8 (13%) 73 (23%) NSD
Chemoresistance, Cross-Resistance, and Combinations of Agents to Overcome Resistance
9. Chemotherapy resistance,
cross-resistance, and combinations
to overcome resistance
39 (65%) 29 (73%) 27 (68%) 27 (66%) 24 (60%) 32 (78%) 32 (53%) 210 (65%) NS
Abbreviations: CHN ¼ China; CRC ¼ colorectal cancer; FRA ¼ France; GER ¼ Germany; ITA ¼ Italy; SP ¼ Spain; UK ¼ United Kingdom.
aSigniﬁcant differences between pairs of countries using analysis of variance (ANOVA) and Tahmane T2 post hoc tests (P < .05). NS (not signiﬁcant) indicates measures for which the ANOVA was not signiﬁcant, and thus, for which the post hoc tests were not performed. NSD
(no speciﬁc difference) indicates measures for which the ANOVA was signiﬁcant, but speciﬁc post hoc differences could not be identiﬁed.
bSigniﬁcant differences between countries (c2; P < .05).
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Table 5 The Number and Percentage of Oncologists in Each Country Reporting Speciﬁc Skill Items as Essential to Their Role (First Series of Numbers for Each Item) and Among Those, the
number and Percentage Reporting a Need for Improvement (Second Series of Numbers for Each Item)
Skill
Participants Reporting the Skill as Essential to Their Role, n(%) /as Needing Improvement, n (%)
CHN
(n [ 60)
FRA
(n [ 40)
GER
(n [ 40)
ITA
(n [ 41)
SP
(n [ 40)
UK
(n [ 41)
US
(n [ 60)
Total
(n [ 322)
Signiﬁcant
Differencea
Mutation Analysis (Use and Access) and Subsequent Adaptation of Treatment Selection
1. Adapting treatment recommendations to
mutation analysis resultsb
21 (35%) 26 (65%) 20 (50%) 21 (51%) 31 (78%) 26 (63%) 44 (73%) 189 (59%) SP > CHN;
US > CHN
17 (81%) 12 (46%) 17 (85%) 13 (62%) 22 (71%) 17 (65%) 23 (52%) 121 (64%) NSD
Optimal Sequencing of the Different Treatment Options
2. Sequencing treatment options 25 (42%) 15 (38%) 23 (58%) 24 (59%) 22 (55%) 27 (66%) 42 (70%) 178 (55%) US > CHN;
US > FR
18 (72%) 11 (73%) 14 (61%) 15 (63%) 10 (46%) 15 (56%) 21 (50%) 104 (58%) NS
Individualizing Treatment Based on Patient and Tumor Proﬁle
3. Identifying patients who will not beneﬁt
from chemotherapy after surgery
25 (42%) 22 (55%) 28 (70%) 23 (56%) 34 (85%) 37 (90%) 46 (77%) 215 (67%) SP > CHN;
UK > CHN;
US > CHN;
UK > FR;
UK > ITA
17 (68%) 11 (50%) 14 (50%) 10 (44%) 22 (65%) 16 (43%) 28 (61%) 118 (55%) NS
4. Accurately identifying patients with
metastatic colorectal cancer who are
candidates for curative intent managementb
38 (63%) 30 (75%) 34 (85%) 27 (66%) 38 (95%) 38 (93%) 51 (85%) 256 (80%) SP > CHN;
UK > CHN;
SP > ITA
31 (82%) 17 (57%) 15 (44%) 17 (63%) 20 (53%) 17 (45%) 24 (47%) 141 (55%) CHN > GER;
CHN > UK;
CHN > US
5. Adjusting the treatment plan based
on the precise staging of the cancerb
41 (68%) 28 (70%) 35 (88%) 20 (49%) 35 (88%) 37 (90%) 54 (90%) 250 (78%) GER > ITA;
SP > ITA;
UK > ITA;
US > ITA
25 (61%) 17 (61%) 13 (37%) 8 (40%) 12 (34%) 7 (19%) 13 (24%) 95 (38%) CHN > UK;
FRA > UK;
CHN > US;
FRA > US
6. Identifying patients who will beneﬁt from
radiation therapy in rectal cancerb
30 (50%) 28 (70%) 30 (75%) 23 (56%) 30 (75%) 32 (78%) 47 (78%) 220 (68%) US > CHN
21 (70%) 9 (32%) 15 (50%) 10 (44%) 13 (43%) 7 (22%) 18 (38%) 93 (42%) CHN > UK
7. Identifying patients who will beneﬁt from
combination therapyb
34 (57%) 25 (63%) 30 (75%) 25 (61%) 33 (83%) 31 (76%) 49 (82%) 227 (71%) NSD
21 (62%) 9 (36%) 10 (33%) 11 (44%) 16 (49%) 8 (26%) 14 (29%) 89 (39%) NSD
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Table 5 Continued
Skill
Participants Reporting the Skill as Essential to Their Role, n(%) /as Needing Improvement, n (%)
CHN
(n [ 60)
FRA
(n [ 40)
GER
(n [ 40)
ITA
(n [ 41)
SP
(n [ 40)
UK
(n [ 41)
US
(n [ 60)
Total
(n [ 322)
Signiﬁcant
Differencea
8. Taking into account all comorbidities
(cardiac risk, liver problems, diabetes)
when recommending a treatment plan
33 (55%) 24 (60%) 29 (73%) 20 (49%) 28 (70%) 35 (85%) 51 (85%) 220 (68%) UK > CHN; US >
CHN; UK > ITA; US
> ITA
22 (67%) 12 (50%) 13 (45%) 7 (35%) 13 (46%) 11 (31%) 20 (39%) 98 (45%) NS
Management of Side Effects and Toxicities
9. Early detection of treatment side effectsb 18 (30%) 24 (60%) 30 (75%) 22 (54%) 28 (70%) 34 (83%) 40 (67%) 196 (61%) GER > CHN;
SP > CHN;
UK > CHN;
US > CHN
13 (72%) 9 (38%) 9 (30%) 8 (36%) 7 (25%) 9 (27%) 10 (25%) 65 (33%) CHN > SP;
CHN > UK;
CHN > US
10. Assessing treatment effect on patient’s
quality of life to optimally inform treatment
modiﬁcationsb
35 (58%) 17 (43%) 24 (60%) 19 (46%) 26 (65%) 36 (88%) 42 (70%) 199 (62%) UK > CHN;
UK > FRA;
UK > ITA
20 (57%) 12 (71%) 12 (50%) 7 (37%) 9 (35%) 12 (33%) 11 (26%) 83 (42%) FRA > US
Abbreviations: CHN ¼ China; FRA ¼ France; GER ¼ Germany; ITA ¼ Italy; SP ¼ Spain; UK ¼ United Kingdom.
aSigniﬁcant differences between pairs of countries using analysis of variance (ANOVA) and Tahmane T2 post hoc tests (P < .05). NS (not signiﬁcant) indicates measures for which the ANOVA was not signiﬁcant, and thus, for which the post hoc tests were not performed.
NSD (no speciﬁc difference) indicates measures for which the ANOVA was signiﬁcant, but speciﬁc post hoc differences could not be identiﬁed.
bSigniﬁcant differences between countries for percentage needing improvement (c2; P < .05); country differences for relevance were signiﬁcant for all items presented (c2; P < .05).
P
atrice
L
azure
et
al
ClinicalColorectalCancer
March
2016 -61
Table 6 Number and Percentage of Oncologists in Each Country Reporting Speciﬁc Conditions as Creating Important Levels of Challenge in Their Treatment Decisions
Condition
Oncologists Reporting a Signiﬁcant Challenge, n (%)a
CHN
(n [ 60)
FRA
(n [ 40)
GER
(n [ 40)
ITA
(n [ 41)
SP
(n [ 40)
UK
(n [ 41)
US
(n [ 60)
Total
(n [ 322) Mean (SD)
Comorbidities
1. My patient has a chronic
respiratory comorbidity
10 (17%) 6 (15%) 7 (18%) 0 (0%) 10 (25%) 6 (15%) 14 (23%) 52 (16%) 2.75 (0.88)
2. My patient has a cardiac
comorbidity
26 (43%) 15 (38%) 21 (53%) 15 (37%) 25 (63%) 25 (63%) 22 (37%) 151 (47%) 3.31 (1.02)
3. My patient has liver or lung
metastases
24 (40%) 7 (18%) 24 (60%) 3 (7%) 7 (18%) 10 (24%) 25 (42%) 100 (31%) 2.75 (1.26)
4. My patient is taking multiple
medications for other conditions
10 (17%) 6 (15%) 12 (30%) 2 (5%) 6 (15%) 11 (27%) 15 (25%) 61 (19%) 2.70 (0.96)
Resistance
5. My patient has previously
received chemotherapy and possibly
developed resistance
29 (48%) 7 (18%) 23 (58%) 4 (10%) 11 (28%) 16 (41%) 22 (37%) 113 (35%) 3.05 (1.08)
Medication
6. The medication I am considering
is not reimbursed for my patient
22 (37%) 23 (58%) 17 (43%) 21 (51%) 16 (40%) 22 (54%) 38 (63%) 158 (49%) 3.43 (1.31)
7. The medication I am considering
requires a very time consuming
application for reimbursement
27 (45%) 20 (50%) 16 (40%) 17 (41%) 17 (43%) 13 (32%) 33 (55%) 142 (44%) 3.24 (1.18)
8. The medication I am considering
is approved for another condition,
but not for CRC (off-label use)
27 (45%) 20 (50%) 24 (60%) 22 (54%) 20 (50%) 26 (66%) 35 (58%) 174 (54%) 3.55 (1.11)
9. The medication I am considering
is available only through clinical
trials
25 (42%) 21 (53%) 22 (55%) 21 (51%) 25 (63%) 20 (49%) 47 (78%) 180 (56%) 3.61 (1.10)
Abbreviations: CHN ¼ China; CRC ¼ colorectal cancer; FRA ¼ France; GER ¼ Germany; ITA ¼ Italy; SP ¼ Spain; UK ¼ United Kingdom.
aParticipants were asked to rate the level of challenge of each item on a challenge scale of 1 (no challenge) to 5 (major challenge). Data are the percentage of oncologists who responded 4 or 5. Means and standard deviations are of all answers, from the full sample. Ranges
of answers obtained were from 1 to 5 for all items.
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Patrice Lazure et alwas an essential skill to their practice (Table 5, item 1). Of those
who rated the skill as essential, 64% (n:121) reported their skill level
needed at least minor improvement. Relevance of mutation analysis
was different between countries, with 35% of oncologists in China
(n:21) who perceived a relevance to their role compared with 78%
in Spain (n:31).
Optimal Sequencing of Treatment Choices
Among the topics presented, knowledge of optimal sequencing
and combination of treatment was selected by the second highest
proportion of respondents (n:161; 50%) as being challenging to
keep up with current evidence (Table 3). This was the case in all 7
countries. When asked speciﬁcally about sequencing of agents after
surgery, 26% (n:83) reported their knowledge to be unacceptable or
needing improvement (Table 4, item 2).
A lack of skill was reported in sequencing treatment options,
because 58% (104/178) of those who reported the skill as essential
reported needing improvement (Table 5, item 2). In Germany,
Italy, Spain, the United Kingdom, and the United States, re-
spondents reported the skill as essential in proportions ranging from
55% to 70%. Lower proportions of oncologists reported this skill as
essential in China (n:25; 42%) and France (n:15; 38%).
Potential causes reported qualitatively by oncologists for this chal-
lenge were: the plethora of emerging new agents, limited published
evidence, and lack of comfort using a trial and error process in the
absence of solid evidence to guide sequencing of treatment options.
Individualizing Treatment Based on the Patient and
Tumor Proﬁle
More than one-third of respondents reported that their level of
knowledge could be improved on 3 different items related to
individualization (Table 4, items 3-5): best practices for the treat-
ment of patients with severe comorbid conditions (n:142; 44%),
best treatment combination for each individual patient (n:120;
37%), and proﬁle of patients who will respond best to each available
therapeutic option (n:131; 41%). For these 3 knowledge items,Figure 1 Illustration of the Gaps That Hinder the Translation of Rec
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Abbreviations: C ¼ Context; CRC ¼ Colorectal Cancer; K¼ Knowledge; S ¼ Skill; SEs ¼ Side Effeneed for improvement was reported in a lower proportion of on-
cologists in Italy (n:13; 32%, n:16; 39%, and n:13; 32%, respec-
tively), and in a higher proportion in France (n:25; 63%, n:20;
50%, and n:20; 50%, respectively). Knowledge of best practices for
the treatment of patients older than the age of 70 years was reported
as not acceptable or could be improved by 87 (27%) oncologists.
For the following 2 skills related to individualization of treat-
ment, over half of oncologists reported the skills as relevant to their
practice but needing improvement (Table 5, items 3-4): identiﬁ-
cation of patients who will not beneﬁt from chemotherapy after
surgery (n:215; 67% relevance; n:118; 55% needing improvement),
and accurate identiﬁcation of patients with metastatic CRC who are
candidates for curative intent management (n:256; 80% relevance;
n:141; 55% needing improvement).
More than one-third of oncologists perceived the following 4 skills
related to the individualization of treatment as relevant but needing
improvement (Table 5, items 5-8): adjustment of the treatment plan
on the basis of precise staging of the cancer (n:250; 78% relevance;
n:95; 38% needing improvement), identiﬁcation of patients who will
beneﬁt from radiation therapy in rectal cancer (n:220; 68% relevance;
n:93; 42% needing improvement), identiﬁcation of patients who will
beneﬁt from combination therapy (n:227; 71% relevance; n:89; 39%
needing improvement), and taking into account all comorbidities
when recommending a treatment plan (n:220; 68% relevance; n:98;
45%needing improvement). For 3 of these 4 skill items (the exception
being identiﬁcation of patients who will beneﬁt from combination
therapy), relevance was higher and need for improvement lower in the
United Kingdom and the United States, and relevance was lower in
Italy, and need for improvement was higher in France and China.
When asked about patient comorbidities, cardiac comorbidities
were reported as posing the greatest challenge for oncologists (ie, 4-5
on a scale from 1 ¼ no challenge to 5 ¼ major challenge) in all
countries, except Germany and the United States (Table 6, items
1-4). In Germany and the United States, liver or lung metastases
were associated with the highest proportion of participants who
reported an important challenge.ent Advances in Improvement of Clinical Outcomes
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64 -Management of Side Effects and Toxicities
Need for improvement was reported for level of knowledge
regarding side effects associated with each CRC treatment option
(n:76; 24%) and toxicity associatedwith available combination therapy
(n:73; 23%) (Table 4, items 7-8). More than one-third of oncologists
from China (n:22; 37%) and Germany (n:15; 38%) reported their
knowledge of side effects associated with CRC treatment options could
be improved in contrast to 7% (n:3) in the United Kingdom.
Two skills related to management of side effects and toxicities were
reported as needing improvement by more than one-third of oncol-
ogists who perceived these skills as relevant (Table 5, items 9-10):
early detection of treatment side effects (n:196; 61% relevance; n:65;
33% needing improvement) and assessment of treatment effects on
the patient’s quality of life to optimally inform treatment modiﬁca-
tions (n:199; 62% relevance; n:83; 42% needing improvement).
There were different levels of relevance reported for early detection of
treatment side effects, with this skill being reported as relevant by
83% of oncologists from the United Kingdom (n:36) and 30% of
oncologists from China (n:18). Furthermore, reported level of skill
differed according to country, with 25% of oncologists from Spain
(7/28) and the United States (10/40) reporting a need for improve-
ment, and 72% of oncologists in China who perceived the skill as
relevant reported a need for improvement (13/18). Reported rele-
vance and skill differed according to country for assessment of
treatment effects on patients’ quality of life to optimally inform
treatment modiﬁcations, with participants from the United Kingdom
reporting the highest relevance (n:36; 88%), and participants from
France reporting the highest need for improvement (12/17; 71%).
Chemoresistance, Cross-Resistance, and Combinations to
Overcome Resistance
Most oncologists (n:210; 65%) reported that their knowledge of
chemoresistance, cross-resistance, and combinations to overcome
resistance needed at least minor improvement (Table 4, item 9).
This proportion was > 50% in all countries surveyed. Patients who
previously received chemotherapy and possibly developed resistance
were reported as creating an important challenge (ie, 4-5 on a scale
from 1 ¼ no challenge to 5 ¼ major challenge) by more than one-
third of oncologists (n:113; 35%) (Table 6, item 5). Differences
according to country were observed, with 58% of oncologists from
Germany (n:23) who reported an important challenge, compared
with 10% in Italy (n:4) and 18% in France (n:7).
Access to New Emerging Treatments
Oncologists reported experiencing important challenges with
different aspects of access to treatments (ranging from 44% to 56%;
Table 6, items 6-9). Differences between countries were observed
for the level of challenge associated with nonreimbursement, with
the United States (n:38; 63%) and France (n:23; 58%) being the 2
countries that reported an important challenge in the highest pro-
portion. Access to agents in clinical trials was also different between
countries, with a higher proportion of oncologists reporting a
challenge in the United States (n:47; 78%).
Discussion
This international assessment of educational needs identiﬁed
several perceived challenges reported by oncologists in the treatmentClinical Colorectal Cancer March 2016and management of patients with CRC. It is one of the ﬁrst studies
to investigate perceived gaps in practice across multiple countries,
and interestingly enough, many of the reported challenges were
present across countries. The ﬁndings from this assessment illustrate
how changes in the environment, mainly the growing literature on
mutation analysis and the increased number of therapeutic agents
available, have added complexity to CRC treatment and manage-
ment. Figure 1 illustrates how these recent advances should ideally
lead to better outcomes (left portion), and how the gaps and chal-
lenges reported in this study can constitute barriers on the path from
scientiﬁc advances to improvement of clinical outcomes (right
portion). The following discussion demonstrates the links between
the different components of Figure 1, and the ﬁndings of this study.
Although the results presented herein only show an access issue in
relation to treatment, it can be hypothesized that, at least in certain
countries, an access issue might also prevent use of mutation anal-
ysis. Access is also dependent on decisions taken at the health system
level, such as regulatory agency decisions regarding approval of a
new agent. In addition, testing of many mutations is considered
standard in Europe but not in the United States, therefore making
mutation analysis more accessible in Europe.
Each new agent comes with its own resistance mechanisms, and
its own potential side effects and toxicities, and creates a need for
oncologists to constantly update their knowledge. With more agents
at their disposal, oncologists face increasing possibilities with respect
to treatment combinations and sequences and therefore more op-
tions to overcome resistance, or to individualize the treatment based
on the mutation proﬁle of the tumor.
Rapid increases of scientiﬁc knowledge on mutation analysis have
been reported in many cancer types, with studies on analysis of large
numbers of mutations with the aim of cataloguing the mutations,
and linking them to different patient and tumor characteristics.27-29
Literature reviews summarizing progress in the mutational proﬁling
of tumors have recently been published in breast cancer,30 lung
cancer,31 and prostate cancer.32 A number of new agents have been
developed and approved not only in CRC, but for many other
cancer types.14,33,34 Thus, the challenges reported herein might not
be unique to CRC but applicable in other cancer types.
The knowledge and skill challenges identiﬁed in this study
regarding mutation analysis might have different causalities
depending on the country. In China, the fact that adapting treat-
ment to mutation analysis was not perceived as essential could be
related to the limited access some of the responding oncologists
might have to such tests. The different levels of self-reported rele-
vance by the oncologists of the different countries could also be
linked to differences in the composition of the oncology team, and
the level of collaboration within these teams, which might vary
between countries and affect oncologists’ roles and responsibilities.
Finally, regulatory approval status of mutation- and/or marker-
speciﬁc drugs in different countries could also inﬂuence the
perceived relevance of mutation analysis.
The introduction of new and improved mutation analysis tech-
niques in oncology practice is likely to increase the possibility of
obtaining a more precise proﬁle of the tumor, including the mu-
tation status of molecular targets in each individual patient, and
their evolution during treatment, rendering personalized oncology a
reality.35 For that reality to truly affect treatment outcomes, the
Patrice Lazure et alchallenges experienced by oncologists through this rapidly evolving
environment must be identiﬁed and addressed appropriately.
Future Studies
A follow-up study is currently being deployed by the coauthors
with radiotherapists to explore their gaps and challenges as physi-
cians who oversee, prescribe, deliver and/or plan radiation treatment
for cancer. A more detailed and precise investigation of oncologists’
knowledge gaps is also currently being deployed, to further inform
educational activities.
Limitations
Because the goals of this assessment were to identify challenges and
barriers, less attention was given to areas in which care is optimal.
Because the method was based on self-report, there is the possibility of
bias due to erroneous self-assessment. Self-selection bias was also a
possibility, because participation in the study was voluntary. The
different roles and responsibilities of oncologists, and the different
health systems across multiple countries could have inﬂuenced
perceived relevance of the different knowledge and skill items pre-
sented. However, in this study we applied research on clinical chal-
lenges faced by oncologists in their respective clinical context; the aim
was not to form a homogeneous sample. In addition, triangulation
with qualitative data allowed the coauthors to interpret ﬁndings in
light of the oncologist’s role and health system described in each
country, which strengthened the trustworthiness of the ﬁndings.
Conclusion
This international behavioral needs assessment identiﬁed gaps that
represent important areas of focus for future educational in-
terventions. The ﬁndings suggest that oncologists who treat and
manage patients with CRC are challenged to optimally integrate
recent advances in mutation analysis, the effect of mutations on the
efﬁcacy of therapeutic agents, and the numerous options available to
design more individualized treatment plans into their practice.
Despite country-speciﬁc differences, common challenges were
identiﬁed across the targeted countries, demonstrating the possibility
of international educational design and local adaptation. Findings
should stimulate self-reﬂection and dialogue among oncologists on
their practice gaps, and on how they integrate emerging evidence into
their practice. Furthermore, the model presented in this article could
be used by pharmaceutical and mutation analysis companies to
proactively address potential gaps that create barriers in the path
between their scientiﬁc advancement and improved delivery of care.
Clinical Practice Points
 In recent years, rapid advances inmutation analysis, combined with
the approval of several new agents by national agencies such as the
FDA, have created clinical challenges for oncologists, as they address
the growing potential for individualization of CRC treatment.
 The design ofmore individualized treatment plans for patients with
CRC is hindered by reported gaps in oncologists’ knowledge of
recent advances in mutation analysis, and of the effect of these
mutations on the efﬁcacy of therapeutic agents.Gaps in oncologists’
skills to integrate this information efﬁciently in their decision-
making also affects the provision of individualized treatment. Presentation of these gaps could stimulate self-reﬂection and
dialogue among oncologists regarding how they integrate
emerging evidence into their practice, and inform the develop-
ment of appropriate continuing medical education.Acknowledgments
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